203 related articles for article (PubMed ID: 26554010)
1. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.
Gao X; Zhao Y; Stemmer-Rachamimov AO; Liu H; Huang P; Chin S; Selig MK; Plotkin SR; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):14676-81. PubMed ID: 26554010
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF treatment improves neurological function in tumors of the nervous system.
Zhang N; Chen J; Ferraro GB; Wu L; Datta M; Jain RK; Plotkin SR; Stemmer-Rachamimov A; Xu L
Exp Neurol; 2018 Jan; 299(Pt B):326-333. PubMed ID: 28911884
[TBL] [Abstract][Full Text] [Related]
3. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Zhao Y; Liu P; Zhang N; Chen J; Landegger LD; Wu L; Zhao F; Zhao Y; Zhang Y; Zhang J; Fujita T; Stemmer-Rachamimov A; Ferraro GB; Liu H; Muzikansky A; Plotkin SR; Stankovic KM; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2077-E2084. PubMed ID: 29440379
[TBL] [Abstract][Full Text] [Related]
4. Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.
Zhang N; Gao X; Zhao Y; Datta M; Liu P; Xu L
J Rare Dis Res Treat; 2016; 1(2):51-55. PubMed ID: 28191549
[TBL] [Abstract][Full Text] [Related]
5. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Chen J; Landegger LD; Sun Y; Ren J; Maimon N; Wu L; Ng MR; Chen JW; Zhang N; Zhao Y; Gao X; Fujita T; Roberge S; Huang P; Jain RK; Plotkin SR; Stankovic KM; Xu L
Nat Protoc; 2019 Feb; 14(2):541-555. PubMed ID: 30617350
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Wong HK; Lahdenranta J; Kamoun WS; Chan AW; McClatchey AI; Plotkin SR; Jain RK; di Tomaso E
Cancer Res; 2010 May; 70(9):3483-93. PubMed ID: 20406973
[TBL] [Abstract][Full Text] [Related]
8. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
9. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
11. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
12. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
[TBL] [Abstract][Full Text] [Related]
13. A Xenograft Model of Vestibular Schwannoma and Hearing Loss.
Dinh CT; Bracho O; Mei C; Bas E; Fernandez-Valle C; Telischi F; Liu XZ
Otol Neurotol; 2018 Jun; 39(5):e362-e369. PubMed ID: 29557843
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence.
Renzi S; Michaeli O; Salvador H; Alderete D; Ponce NF; Zapotocky M; Hansford JR; Malalasekera VS; Toledano H; Maguire B; Bouffet E; Ramaswamy V; Baroni LV
Pediatr Blood Cancer; 2020 May; 67(5):e28228. PubMed ID: 32124552
[TBL] [Abstract][Full Text] [Related]
15. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
Sponghini AP; Platini F; Rondonotti D; Soffietti R
Tumori; 2015 Nov; 101(6):e167-70. PubMed ID: 26108240
[TBL] [Abstract][Full Text] [Related]
20. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma.
Lustig LR; Yeagle J; Driscoll CL; Blevins N; Francis H; Niparko JK
Otol Neurotol; 2006 Jun; 27(4):512-8. PubMed ID: 16791043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
